311 related articles for article (PubMed ID: 16356870)
1. The leukocyte count predicts the efficacy of treatment with azathioprine in inflammatory bowel disease.
Glas J; Török HP; Daczo J; Tonenchi L; Folwaczny M; Folwaczny C
Eur J Med Res; 2005 Dec; 10(12):535-8. PubMed ID: 16356870
[TBL] [Abstract][Full Text] [Related]
2. 6-tioguanine monitoring in steroid-dependent patients with inflammatory bowel diseases receiving azathioprine.
Roblin X; Serre-Debeauvais F; Phelip JM; Faucheron JL; Hardy G; Chartier A; Helluwaert F; Bessard G; Bonaz B
Aliment Pharmacol Ther; 2005 Apr; 21(7):829-39. PubMed ID: 15801918
[TBL] [Abstract][Full Text] [Related]
3. Monitoring 6-thioguanine nucleotide concentrations in Japanese patients with inflammatory bowel disease.
Andoh A; Tsujikawa T; Ban H; Hashimoto T; Bamba S; Ogawa A; Sasaki M; Saito Y; Fujiyama Y
J Gastroenterol Hepatol; 2008 Sep; 23(9):1373-7. PubMed ID: 18662197
[TBL] [Abstract][Full Text] [Related]
4. [Compared azathioprine efficacy in ulcerative colitis and in Crohn's disease].
Kull E; Beau P
Gastroenterol Clin Biol; 2002 Apr; 26(4):367-71. PubMed ID: 12070412
[TBL] [Abstract][Full Text] [Related]
5. A report on efficacy and safety of azathioprine in a group of inflammatory bowel disease patients in northwest Greece.
Christodoulou D; Katsanos K; Baltayannis G; Tzabouras N; Tsianos EV
Hepatogastroenterology; 2003; 50(52):1021-4. PubMed ID: 12845970
[TBL] [Abstract][Full Text] [Related]
6. A single center experience of methotrexate in the treatment of Crohn's disease and ulcerative colitis: a case for subcutaneous administration.
Nathan DM; Iser JH; Gibson PR
J Gastroenterol Hepatol; 2008 Jun; 23(6):954-8. PubMed ID: 17559377
[TBL] [Abstract][Full Text] [Related]
7. Unfractioned heparin in the therapy of patients with highly active inflammatory bowel disease.
Folwaczny C; Wiebecke B; Loeschke K
Am J Gastroenterol; 1999 Jun; 94(6):1551-5. PubMed ID: 10364024
[TBL] [Abstract][Full Text] [Related]
8. Immunosuppressive therapy in pediatric inflammatory bowel disease: results of a survey of the North American Society for Pediatric Gastroenterology and Nutrition. Subcommittee on Immunosuppressive Use of the Pediatric IBD Collaborative Research Forum.
Markowitz J; Grancher K; Mandel F; Daum F
Am J Gastroenterol; 1993 Jan; 88(1):44-8. PubMed ID: 8420272
[TBL] [Abstract][Full Text] [Related]
9. Predicting the need for azathioprine at first presentation in children with inflammatory bowel disease.
Mossop H; Davies P; Murphy MS
J Pediatr Gastroenterol Nutr; 2008 Aug; 47(2):123-9. PubMed ID: 18664861
[TBL] [Abstract][Full Text] [Related]
10. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.
Caprilli R; Angelucci E; Cocco A; Viscido A; Annese V; Ardizzone S; Biancone L; Castiglione F; Cottone M; Meucci G; Paoluzi P; Papi C; Sturniolo GC; Vecchi M
Dig Liver Dis; 2005 Jun; 37(6):407-17. PubMed ID: 15893279
[TBL] [Abstract][Full Text] [Related]
11. Intravenous azathioprine in severe ulcerative colitis: a pilot study.
Mahadevan U; Tremaine WJ; Johnson T; Pike MG; Mays DC; Lipsky JJ; Sandborn WJ
Am J Gastroenterol; 2000 Dec; 95(12):3463-8. PubMed ID: 11151878
[TBL] [Abstract][Full Text] [Related]
12. Tacrolimus is safe and effective in patients with severe steroid-refractory or steroid-dependent inflammatory bowel disease--a long-term follow-up.
Baumgart DC; Pintoffl JP; Sturm A; Wiedenmann B; Dignass AU
Am J Gastroenterol; 2006 May; 101(5):1048-56. PubMed ID: 16573777
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of azathioprine in mild or moderate relapse in Crohn's disease: clinical and endoscopic evaluation.
Murakami Y; Matsui T; Hirai F; Takatsu N; Takaki Y; Nagahama T; Hisabe T; Beppu T; Miyaoka M; Maki S; Takeichi M; Nishimura T; Ueki T; Yao K
Dig Endosc; 2010 Jan; 22(1):25-32. PubMed ID: 20078661
[TBL] [Abstract][Full Text] [Related]
14. Long-term results with azathioprine therapy in patients with corticosteroid-dependent Crohn's disease: open-label prospective study.
Chebli JM; Gaburri PD; De Souza AF; Pinto AL; Chebli LA; Felga GE; Forn CG; Pimentel CF
J Gastroenterol Hepatol; 2007 Feb; 22(2):268-74. PubMed ID: 17295882
[TBL] [Abstract][Full Text] [Related]
15. Azathioprine dose escalation in inflammatory bowel disease.
Rayner CK; Hart AL; Hayward CM; Emmanuel AV; Kamm MA
Aliment Pharmacol Ther; 2004 Jul; 20(1):65-71. PubMed ID: 15225172
[TBL] [Abstract][Full Text] [Related]
16. A 6-thioguanine nucleotide threshold level of 400 pmol/8 x 10(8) erythrocytes predicts azathioprine refractoriness in patients with inflammatory bowel disease and normal TPMT activity.
Roblin X; Peyrin-Biroulet L; Phelip JM; Nancey S; Flourie B
Am J Gastroenterol; 2008 Dec; 103(12):3115-22. PubMed ID: 19086961
[TBL] [Abstract][Full Text] [Related]
17. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review.
Fraser AG; Orchard TR; Jewell DP
Gut; 2002 Apr; 50(4):485-9. PubMed ID: 11889067
[TBL] [Abstract][Full Text] [Related]
18. The use of thiopurines for the treatment of inflammatory bowel diseases in clinical practice.
Saibeni S; Virgilio T; D'Incà R; Spina L; Bortoli A; Paccagnella M; Peli M; Sablich R; Meucci G; Colombo E; Benedetti G; Girelli CM; Casella G; Grasso G; de Franchis R; Vecchi M
Dig Liver Dis; 2008 Oct; 40(10):814-20. PubMed ID: 18479986
[TBL] [Abstract][Full Text] [Related]
19. The utility of 6-thioguanine metabolite levels in managing patients with inflammatory bowel disease.
Goldenberg BA; Rawsthorne P; Bernstein CN
Am J Gastroenterol; 2004 Sep; 99(9):1744-8. PubMed ID: 15330913
[TBL] [Abstract][Full Text] [Related]
20. Immunosuppressive agents in the treatment of Crohn's disease and ulcerative colitis.
Hibi T; Iwao Y; Yajima T; Inoue N; Ueno Y; Takaishi H; Watanabe M; Ishii H
J Gastroenterol; 1995 Nov; 30 Suppl 8():121-3. PubMed ID: 8563872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
